Clinical Trials Sponsored by ICONA Foundation

Total 16074 results

Oculis
ICON plc

Recruiting

Study of the Efficacy and Safety of OCS-01 Eye Drops in Subjects With Diabetic Macular Edema (DIAMOND-2)

Diabetic Macular Edema

United States
Adaptimmune
ICON plc

Recruiting

ADP-A2M4CD8 as Monotherapy or in Combination With Either Nivolumab or Pembrolizumab in HLA-A2+ Subjects With MAGE-A4 Positive Tumors (SURPASS)

Melanoma | Head and Neck Cancer | Esophageal Cancer | Ovarian Cancer | Endometrial Cancer | Urothelial Cancer | Gastric (Stomach) Cancer | Esophagogastric Junction (EGJ) | Non-small Cell Lung (NSCLC)

United States, Canada, Spain, Belgium
GlaxoSmithKline
ICON plc

Completed

Study of Subjects With Diabetic Foot Ulcer (DFU)

Diabetic Foot

United States
ICON Bioscience Inc

Completed

Efficacy and Safety of IBI-10090 in Ocular Surgery Patients

Inflammation Associated With Cataract Surgery

United States
GlaxoSmithKline
ICON plc

Completed

FF/UMEC/VI Inhaler: Qualitative Analysis and Subject Preference Survey

Pulmonary Disease, Chronic Obstructive

United Kingdom
Mallinckrodt
ICON plc

Completed

Safety and Efficacy of Extracorporeal Photoimmune Therapy With UVADEX for the Treatment of Crohn's Disease

Crohn's Disease

Belgium, Germany, United States, Austria
Icon Genetics GmbH

Completed

Autologous Vaccine for Follicular Lymphoma

Lymphoma, Follicular

United States
ICON Bioscience Inc

Terminated

Efficacy and Safety Study of IBI-10090 in Cataract Surgery Patients

Ocular Inflammation

United States
AstraZeneca
ICON plc

Not yet recruiting

Non-interventional Study of Patients With Transthyretin (ATTR) Amyloidosis (MaesTTRo)

Transthyretin Amyloidosis | ATTR-CM | ATTRv-PN | ATTR | ATTR-Mixed | hATTR
AstraZeneca
ICON plc

Recruiting

Observational Study Protocol: LIVER-R (LIVER-R)

Hepatobiliary Cancers

United States, Greece, Puerto Rico, Germany, Italy, France
Adaptimmune
ICON plc

Terminated

ADP-A2M4CD8 in HLA-A2+ Subjects With MAGE-A4 Positive Esophageal or Esophagogastric Junction Cancers (SURPASS-2)

Esophageal Cancer | Esophagogastric Junction Cancer

United States, Canada, Spain
ICON Bioscience Inc

Terminated

Efficacy and Safety Study of IBI-10090 in Patients Undergoing Cataract Surgery

Inflammatory Reaction Due to Ocular Lens Prosthesis

United States
ICON Bioscience Inc

Completed

Study to Evaluate the Safety for the Treatment of Inflammation Associated With Cataract Surgery

Cataract

United States
ICON Bioscience Inc

Completed

The Efficacy and Safety of IBI-10090 for the Treatment of Inflammation Associated With Cataract Surgery

Inflammation | Cataracts

United States
HighLife SAS
ICON plc

Recruiting

Expanded Study of the HighLife 28mm Trans-septal Trans-catheter Mitral Valve in Patients With Moderate-severe or Severe Mitral Regurgitation and at High Surgical Risk

Mitral Regurgitation

Belgium, France, Germany, Australia, United Kingdom, Poland
Estetra
ICON Clinical Research

Active, not recruiting

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort Study I)

Vasomotor Symptoms | Menopausal Symptoms

Spain, United States, Argentina, Lithuania, Poland, Italy, Hungary, United Kingdom, Romania, Czechia, Brazil, Canada, Russian Federation, Slovakia
Bayer
ICON Clinical Research

Completed

Sorafenib Long Term Extension Program (STEP)

Neoplasms

Spain, Hong Kong, Canada, Germany, France, United States, United Kingdom, Taiwan, New Zealand, Australia, Belgium, China, Bulgaria, Italy, Colombia, Poland, Korea, Republic of, Brazil, Ukraine
GE Healthcare
ICON plc

Completed

A Study to Evaluate the Effectiveness of VIZAMYL™ Reader Training Programme in Europe

Cognitive Impairment

Netherlands, Spain, Austria, Finland, Italy
Xencor, Inc.
ICON plc

Completed

A Study of XmAb®18087 in Subjects With NET and GIST

Neuroendocrine Tumor | Gastrointestinal Neoplasm

United States
GE Healthcare
ICON plc

Completed

Advanced MRI Applications for Mild Traumatic Brain Injury-Phase 2 (mTBI-phase2)

Traumatic Brain Injury | Concussion

United States
Sernova Corp
Juvenile Diabetes Research Foundation; University of Chicago; ICON plc

Recruiting

A Safety, Tolerability and Efficacy Study of Sernova's Cell Pouch™ for Clinical Islet Transplantation

Type 1 Diabetes Mellitus

United States
Tolmar Inc.
ICON plc

Recruiting

A Phase 4 Study to Evaluate Adrenal Function in Hypogonadal Men Treated With JATENZO® for 12 Months

Hypogonadism

United States
JOTEC GmbH
ICON plc

Recruiting

French Registry Conducted on E-vita OPEN NEO (NEO)

Vascular Aneurysm

France
Xencor, Inc.
ICON plc

Recruiting

A Study of XmAb20717 (Vudalimab)in Patients With Selected Advanced Gynecologic and Genitourinary Malignancies

Ovarian Cancer | Endometrial Cancer | Cervical Carcinoma | Metastatic Castration-Resistant Prostate Cancer (mCRPC) | Clear Cell Carcinoma

United States
Xencor, Inc.
ICON plc

Active, not recruiting

A Study of XmAb®23104 in Subjects With Selected Advanced Solid Tumors (DUET-3) (DUET-3)

Renal Cell Carcinoma | Nasopharyngeal Carcinoma | Small Cell Lung Cancer | Hepatocellular Carcinoma | Advanced Solid Tumors | Non-small Cell Lung Carcinoma | Squamous Cell Carcinoma of the Head and Neck | Cervical Carcinoma | Endometrial Carcinoma | Urothelial Carcinoma | Colorectal Carcinoma | Pancreatic Carcinoma and other conditions

United States
Edwards Lifesciences
ICON plc

Terminated

Observational Registry on the HARPOON Device (REPLICATE)

Severe Degenerative Mitral Regurgitation Due to Mid-segment Posterior Leaflet Prolapse

Germany, Spain, Switzerland
LEO Pharma
ICON plc

Completed

A Single and Multiple Ascending-dose Trial of LEO 153339 in Healthy Adults

Healthy Volunteers

Netherlands
Xencor, Inc.
ICON plc

Completed

A Study of XmAb®20717 in Subjects With Selected Advanced Solid Tumors (DUET-2)

Melanoma | Renal Cell Carcinoma | Cervical Cancer | Nasopharyngeal Carcinoma | Small Cell Lung Carcinoma | Hepatocellular Carcinoma | Thymic Carcinoma | Thymoma | Non-small Cell Lung Carcinoma | Mesothelioma | Squamous Cell Carcinoma of the Head and Neck | Cholangiocarcinoma | Breast Carcinoma | Fallopian Tube Carcinoma and other conditions

United States
Vasopharm GmbH
ICON plc

Completed

Efficacy of VAS203 (Ronopterin) in Patients With Moderate and Severe Traumatic Brain Injury (NOSTRA-III)

Traumatic Brain Injury

United Kingdom, Spain, France, Austria, Germany
GE Healthcare
ICON plc

Completed

Comparative Study of Conventional 1.5 and 3.0T MR Images With Synthetically Reconstructed MR Images

Clinical Indication for Brain MRI

United States
Renovo
ICON Clinical Research

Completed

Juvista (Avotermin) in Scars Following Varicose Vein Removal

Cicatrix | Varicose Veins

Belgium, United Kingdom, Latvia, Lithuania
Ilona Myllyniemi
University of Cambridge

Not yet recruiting

Tracking Mood: The Effects of Daily Mood Tracking VAS on Alcohol Consumption in Adult Heavy Drinkers

Alcohol Drinking | Alcohol Dependence | Alcohol Use Disorder | Alcohol Abuse | Alcohol Intoxication
Mediar Therapeutics
ICON plc

Recruiting

A First-in-Human Safety Trial of MTX-463

Healthy

United States
SeaStar Medical
ICON plc

Recruiting

Neutrophil and Monocyte Deactivation Via the SeLective CytopheretIc Device - A Randomized Clinical Trial in Acute Kidney Injury (NEUTRALIZE-AKI)

Acute Kidney Injury

United States
BioMarin Pharmaceutical
ICON plc

Completed

A Multicenter, Multinational, Observational Morquio A Registry Study (MARS) (MARS)

Mucopolysaccharidosis IV Type A | Morquio A Syndrome | MPS IVA

United States, United Kingdom, Australia, Taiwan, Belgium, Malaysia, Austria, Canada, Portugal, France, Ireland, Czechia, Denmark, Italy, Netherlands, Poland, Puerto Rico
AltruBio Inc.
ICON plc

Completed

A First-In-Human SAD and MAD Study to Evaluate the Safety, Tolerability, PK and PD of SC Administered ALTB-268 in Healthy Volunteers

Healthy Volunteers

United States
Fervent Pharmaceuticals
ICON plc

Completed

FP-101 Versus Placebo in the Treatment of Menopausal Vasomotor Symptoms

Vasomotor Symptoms | Menopause

United States
Biocept, Inc.
ICON plc

Terminated

A Therapy Treatment Response Trial in Patients With Leptomeningeal Metastases ((LM) Using CNSide (FORESEE)

Breast Cancer | Non-Small Cell Lung Cancer | Leptomeningeal Disease | Leptomeningeal Metastasis | Leptomeningeal Neoplasms

United States
Estetra
ICON Clinical Research

Completed

Estetrol for the Treatment of Moderate to Severe Vasomotor Symptoms in Postmenopausal Women (E4Comfort)

Vasomotor Symptoms | Menopausal Symptoms

United States, Canada
Xencor, Inc.
ICON plc

Terminated

Safety and Efficacy of XmAb18087 ± Pembrolizumab in Advanced Merkel Cell Carcinoma or Extensive-stage Small Cell Lung Cancer

Small Cell Lung Cancer | Merkel Cell Carcinoma

United States
Actinogen Medical
ICON plc

Completed

Xanamem™ in Healthy Elderly Subjects (XanaHES)

Cognitive Function | Peripheral Neuropathy | Electrocardiography | Central Nervous System | Safety | Healthy Ageing | Cortisol | Cerebrospinal Fluid | Small Fibre Neuropathy

Australia
Celgene
ICON Clinical Research

Completed

Study to Compare the Efficacy and Safety of CC-5013 vs. Placebo in Subjects With Metastatic Malignant Melanoma.

Melanoma | Neoplasm Metastasis

Australia, United Kingdom, Ukraine, Germany, Estonia, Latvia, Lithuania, Netherlands, South Africa
Chiesi Farmaceutici S.p.A.
ICON plc

Recruiting

Study to Evaluate the Safety, PK, PD, and Efficacy of PRX-102 in Japanese Patients With Fabry Disease (RISE)

Fabry Disease

Japan
Pharmacosmos A/S
ICON plc

Recruiting

A Trial Testing SP-420 in Subjects With Transfusion-dependent β-thalassemia

Beta Thalassemia Major Anemia

Denmark
Miltenyi Biomedicine GmbH
ICON plc

Recruiting

Efficacy and Safety of MB-CART2019.1 vs. SoC in Lymphoma Patients (DALY 2-EU)

Diffuse Large B-cell Lymphoma

Spain, Germany, Netherlands, Belgium, France, Czechia, Austria, Lithuania, Sweden, Hungary, Italy, Poland
Nordic Nanovector
ICON Clinical Research

Completed

A Phase 1/2 Study of Betalutin for Treatment of Relapsed Non-Hodgkin Lymphoma (LYMRIT-37-01)

Follicular Lymphoma | Non-Hodgkin Lymphoma

United States, Korea, Republic of, Australia, Austria, Belgium, Canada, Croatia, Czechia, Denmark, Finland, France, Hungary, Ireland, Israel, Italy, Netherlands, Norway, Poland, Singapore, Spain, Sweden, Switzerland, Turkey, United Kingdom
CSL Behring
ICON Clinical Research

Terminated

Clazakizumab for the Treatment of Chronic Active Antibody Mediated Rejection in Kidney Transplant Recipients (IMAGINE)

Antibody-mediated Rejection

Korea, Republic of, United States, New Zealand, Spain, Taiwan, Netherlands, Australia, France, Canada, Belgium, Czechia, Hungary, Sweden, Austria, Germany
Xencor, Inc.
ICON Clinical Research

Active, not recruiting

Study to Evaluate Safety and Tolerability of XmAb13676 (Plamotamab) in Patients With CD20-expressing Hematologic Malignancies

Chronic Lymphocytic Leukemia | B-cell Non-Hodgkins Lymphoma

United States, France, Korea, Republic of, United Kingdom
Mereo BioPharma
ICON Clinical Research

Completed

A Study of Etigilimab and Nivolumab in Subjects With Locally Advanced or Metastatic Tumors.

Advanced Solid Tumor | Metastatic Solid Tumor | Solid Tumor, Adult

United States, United Kingdom
Nordic Nanovector
ICON Clinical Research

Completed

Study of Safety and Efficacy of Betalutin and Rituximab in Patients With FL (LYMRIT-37-07)

Follicular Lymphoma | Non Hodgkin Lymphoma | Relapsed Follicular Lymphoma

Czechia, Norway

Clinical Trials Sponsored by ICONA Foundation

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Jordan

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations